Grace Therapeutics Takes $13.5M Impairment on Deprioritized Pipeline, Extends Cash Runway to 2028
GRCE sits 17% above its 52-week low of $1.79.
Summary
Grace Therapeutics wrote off $13.5 million in intangible assets for its deprioritized GTx-102 and GTx-101 programs, resulting in a $15.8 million quarterly loss. Cash runway extends to 2028 after the August private placement.
Key Events · Earnings and Guidance · GRCE
-
Impairment Charge
Recorded a $13.5 million impairment of GTx-102 and GTx-101 IPR&D, fully writing off their carrying value as the company focuses on GTx-104.
-
Net Loss
Net loss of $15.8 million for the quarter, up from $3.4 million a year earlier, driven primarily by the impairment charge.
-
Cash Runway
Cash and cash equivalents of $22.2 million as of August 11, 2026, after the $9.1 million net proceeds from the August private placement; management expects this funds operations through the end of calendar 2028.
-
Strategic Focus
Company will not resume internal development funding for GTx-102 or GTx-101, retaining IP for potential out-licensing or partnerships.
Analysis · GRCE · Life Sciences
A $13.5 million impairment charge for the GTx-102 and GTx-101 programs was recorded, fully writing off their capitalized value as the company narrows its focus exclusively to GTx-104. The charge drove a net loss of $15.8 million for the quarter, compared with $3.4 million a year earlier. The company also disclosed that its August private placement brought cash to $22.2 million, which management says funds operations through the end of calendar 2028. While the impairment is a non-cash accounting event, it signals a strategic retreat to a single-asset pipeline and removes any near-term value from the two abandoned programs.
At the time of this filing, GRCE was trading at $2.09 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $34.2M. The 52-week trading range was $1.79 to $5.18. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.